Abstract
Deficiencies in the activity of specific pathways for serotonin (5-HT, 5-hydroxytryptamine), and norepinephrine (NE) have long been hypothesized to account for the symptoms of major depressive disorder (MDD). More than 30 years ago, it was noted that pharmacological agents that enhance the availability of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine, produced a clinically meaningful improvement in mood in patients suffering from MDD. This clinical observation led to the development of the so-called 'monoamine hypothesis' of depression, which proposed that functional disruptions in these neurotransmitter systems mediate the behavioural and physiological symptoms (e.g. painful physical symptoms) of depression and related conditions. The pharmacotherapy of MDD has relied principally on the development of agents that alter or increase the functional activity of these classical neurotransmitter systems [1].
Highlights
en/p1I7n4te4r-n8a5t9ioXn-a5l-S1o-cfiueltl.ypdofn">Bhrearine.Burional Congress on Brain and Behaviour Meeting abstracts – A single PDF containing all abstracts in this Supplement is available
Adverse events resulting from the use of such drugs are frequently reported by patients as a reason for stopping treatment
Recent clinical evidence has accumulated that the selective enhancement of both 5-HT and NE systems provide a more robust clinical effect, e.g., in terms of higher remission rates [1]
Summary
en/p1I7n4te4r-n8a5t9ioXn-a5l-S1o-cfiueltl.ypdofn">Bhrearine.Burional Congress on Brain and Behaviour Meeting abstracts – A single PDF containing all abstracts in this Supplement is available
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
